Skip to main content

A multi-center single arm phase II study to evaluate the safety and efficacy of genetically engineered autologous cells expressing anti-CD20 and anti-CD19 specific chimeric antigen receptor in subjects with relapsed and/or refractory diffuse lg Bcell

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Miltenyi Biomedicine

Start Date

February 8, 2022

End Date

January 31, 2027
 

Administered By

Duke Cancer Institute

Awarded By

Miltenyi Biomedicine

Start Date

February 8, 2022

End Date

January 31, 2027